Company Eurofins-Cerep Euronext Paris
Equities
FR0012413771
Biotechnology & Medical Research
Business Summary
Exports account for 97.9% of net sales.
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Preclinical Drug Research Services
100.0
%
| 48 | 100.0 % | 44 | 100.0 % | -7.47% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
International
94.2
%
| 47 | 97.7 % | 41 | 94.2 % | -10.82% |
France
5.8
%
| 1 | 2.3 % | 3 | 5.8 % | +134.99% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 18-04-18 | |
Damien Séroux
CHM | Chairman | - | 14-10-12 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Damien Séroux
CHM | Chairman | - | 14-10-12 |
Director/Board Member | 68 | 15-06-09 | |
Chief Executive Officer | - | 18-04-18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 5,044 | 213 ( 4.223 %) | 0 | 4.223 % |
Company contact information
Eurofins-Cerep SA
Le bois l'Evêque
86600, Celle l'Evescault
+33 5 49 89 30 00
http://www.eurofins.fr/cerep/Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |